Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
The next three weeks are among the rockiest, on a historical basis, of the entire calendar.Trading Nationread more
Of all the cases of economic espionage charged by the DOJ's National Security Division since 2012, more than 80% of them implicated China.World Politicsread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
Ad-tech company The Trade Desk is launching a campaign to show how it differs from tech giants like Google and Facebook.Technologyread more
The streaming wars may have claimed a new victim, and one technical analyst says it could be about to get worse.Trading Nationread more
"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.Singapore Summitread more
No quid pro quo, there was nothing," Trump said the call. "It was a perfect conversation."Politicsread more
On Sunday, the 71st Primetime Emmy Awards honored the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
The UK's Civil Aviation Authority said Thomas Cook had now ceased trading and the regulator would work with the government to bring the more than 150,000 British customers...Europe Marketsread more
Cryptocurrency fans will hope the futures contracts, which are federally regulated, can provide some much-needed legitimacy to bitcoin.Cryptocurrencyread more
The offer of $235 per share in cash represents a premium of about 68 percent to Loxo's Friday close. Loxo's shares surged 66.2 percent to $232.36 on Monday, while Lilly dropped 1.50 percent to $112.94 a share.
"We'd like to grow our presence in oncology. We have a good set of medicines there but we'd like to expand that because there's so much exciting science for patients emerging in oncology to invest in," Lilly CEO David Ricks told CNBC's Jim Cramer on "Squawk on the Street."
Lilly said it will update its financial outlook to include the full purchase price of the acquisition when it announces its fourth-quarter earnings in February. The cost of cash was already worked into its guidance for fiscal year 2019.
Last year, U.S. regulators approved Loxo's first commercial medicine, Vitrakvi, which was shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation. The drug is sold in partnership with Bayer.
President of Lilly Oncology Anne White told analysts on a conference call that the company plans to continue that partnership.
"We believe that Lilly will bring a great deal of strength to this partnership in addition to what Loxo has already done," she said.
Loxo Oncology is developing a pipeline of targeted medicines focused on such cancers that can be detected by genomic testing.
Deutsche Bank is Lilly's financial adviser and Weil, Gotshal & Manges is its legal adviser. Goldman Sachs is the financial adviser, while Fenwick & West is legal adviser to Loxo.
—CNBC's Amelia Lucas contributed to this report.